Commercially available molecular tests for human papillomaviruses (HPV): 2015 update

Journal of Clinical Virology

Volumn 76, Issue , 2016, Pages S3-S13

  Poljak, Mario ^a   Kocjan, Boštjan J ^a   Oštrbenk, Anja ^a   Seme, Katja ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cervical cancer; HPV; Human papillomaviruses; Screening; Test

Indexed keywords

MESSENGER RNA; PROTEIN E6; PROTEIN E7; DIAGNOSTIC KIT;

CLASSIFICATION; DNA SCREENING; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; IN SITU HYBRIDIZATION; MEDLINE; MOLECULAR DIAGNOSTICS; NONHUMAN; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION SYSTEM; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SCOPUS; SCREENING TEST; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VIRUS DIAGNOSIS; WART VIRUS; WEB OF SCIENCE; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COMPLICATION; DIAGNOSTIC KIT; EARLY CANCER DIAGNOSIS; FEMALE; GENETICS; ISOLATION AND PURIFICATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POINT OF CARE SYSTEM; PROCEDURES; SUPPLY AND DISTRIBUTION; UTERINE CERVICAL NEOPLASMS; UTILIZATION; VIROLOGY;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POINT-OF-CARE SYSTEMS; REAGENT KITS, DIAGNOSTIC; UTERINE CERVICAL NEOPLASMS;

EID: 84960457388     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.10.023     Document Type: Review

References (65)

1. Cubie H.A. Diseases associated with human papillomavirus infection. Virology 2013, 445(1-2):21-34.
2. Bernard H.U., Burk R.D., Chen Z., van Doorslaer K., zur Hausen H., de Villiers E.M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401(1):70-79.
3. de Villiers E.M. Cross-roads in the classification of papillomaviruses. Virology 2013, 445(1-2):2-10.
4. Bzhalava D., Eklund C., Dillner J. International standardization and classification of human papillomavirus types. Virology 2015, 476:341-344.
5. Van Doorslaer K., Tan Q., Xirasagar S., Bandaru S., Gopalan V., Mohamoud Y., et al. The Papillomavirus Episteme: a central resource for papillomavirus sequence data and analysis. Nucleic Acids Res. 2013, 41:D571-D578.
6. Arbyn M., Tommasino M., Depuydt C., Dillner J. Are 20 human papillomavirus types causing cervical cancer. J. Pathol. 2014, 234(4):431-435.
7. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al. A review of human carcinogens-part B: biological agents. Lancet Oncol. 2009, 10(4):321-322.
8. Bosch F.X., Broker T.R., Forman D., Moscicki A.-B., Gillison M.L., Doorbar J., et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013, 31(Suppl. 8):I1-I31.
9. Molijn A., Kleter B., Quint W., van Doorn L.J. Molecular diagnosis of human papillomavirus (HPV) infections. J. Clin. Virol. 2005, 32(Suppl. 1):S43-S51.
10. Brink A.A., Snijders P.J., Meijer C.J. HPV detection methods. Dis. Markers 2007, 23(4):273-281.
11. Coutlée F., Mayrand M.H., Roger M., Franco E.L. Detection and typing of human papillomavirus nucleic acids in biological fluids. Public Health Genom. 2009, 12(5-6):308-318.
12. Cox J.T. History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. J. Clin. Virol. 2009, 45(Suppl. 1):S3-S12.
13. Snijders P.J., Heideman D.A., Meijer C.J. Methods for HPV detection in exfoliated cell and tissue specimens. APMIS 2010, 118(6-7):520-528.
14. Arbyn M., Ronco G., Anttila A., Meijer C.J., Poljak M., Ogilvie G., et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012, 30(Suppl. 5):F88-F99.
15. Dillner J. Primary human papillomavirus testing in organized cervical screening. Curr. Opin. Obstet. Gynecol. 2013, 25(1):11-16.
16. Iftner T., Villa L.L. Chapter 12: human papillomavirus technologies. J. Natl. Cancer Inst. Monogr. 2003, 31:80-88.
17. Poljak M., Kocjan B.J. Commercially available tests for multiplex detection of alpha human papillomaviruses. Expert Rev. Anti. Infect. Ther. 2010, 8(10):1139-1162.
18. Poljak M., Cuzick J., Kocjan B.J., Iftner T., Dillner J., Arbyn M. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine 2012, 30(Suppl. 5):F100-F106.
19. Kocjan B.J., Bzhalava D., Forslund O., Dillner J., Poljak M. Molecular methods for identification and characterization of novel papillomaviruses. Clin. Microbiol. Infect. 2015, 21(9):808-816.
20. World Health Organisation, Human papillomavirus laboratory manual, 2009, retrieved 26/10/2015. http://www.who.int/immunization/hpv/learn/hpv_laboratory_manual__who_ivb_2009_2010.pdf.
21. Cuzick J., Bergeron C., von Knebel Doeberitz M., Gravitt P., Jeronimo J., Lorincz A.T., et al. New technologies and procedures for cervical cancer screening. Vaccine 2012, 30(Suppl. 5):F107-F116.
22. Cubie H.A., Cuschieri K. Understanding HPV tests and their appropriate applications. Cytopathology 2013, 24(5):289-308.
23. Carozzi F., Gillio-Tos A., Confortini M., Del Mistro A., Sani C., De Marco L., et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2013, 14(2):168-176.
24. Schiffman M., Clifford G., Buonaguro F.M. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect. Agent. Cancer 2009, 4:8.
25. Castle P.E., Schiffman M., Wheeler C.M., Wentzensen N., Gravitt P.E. Impact of improved classification on the association of human papillomavirus with cervical precancer. Am. J. Epidemiol. 2010, 171(2):155-163.
26. Cuschieri K.S., Cubie H.A. The role of human papillomavirus testing in cervical screening. J. Clin. Virol. 2005, 32(Suppl. 1):S34-S42.
27. Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 2009, 124(3):516-520.
28. Cuschieri K. Human papillomavirus testing: the challenges of picking the right tools for the job. Exp. Rev. Obstet. Gynecol. 2011, 6(6):643-653.
29. Poljak M., Oštrbenk A. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies. Acta Dermatovenerol. Alp. Panonica Adriat. 2013, 22(2):43-47.
30. Poljak M. Towards cervical cancer eradication: joint force of HPV vaccination and HPV-based cervical cancer screening. Clin. Microbiol. Infect. 2015, 21(9):806-807.
31. Arbyn M., Depuydt C., Benoy I., Bogers J., Cuschieri K., Schmitt M., et al. VALGENT: a protocol for clinical validation of human papillomavirus assays. J. Clin. Virol. 2015, HPV Suppl-this issue.
32. Arbyn M., Snijders P.J., Meijer C.J., Berkhof J., Cuschieri K., Kocjan B.J., et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening. Clin. Microbiol. Infect. 2015, 21(9):817-826.
33. Isidean S.D., Coutlée F., Franco E.L. Cobas 4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens. Expert Rev. Mol. Diagn. 2014, 14(1):5-16.
34. Iftner T., Becker S., Neis K.J., Castanon A., Iftner A., Holz B., et al. Head-to-head comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based hybrid capture 2HPV test in a routine screening population of women aged 30-60 years in Germany. J. Clin. Microbiol. 2015, 53(8):2509-2516.
35. Chan P.K., Picconi M.A., Cheung T.H., Giovannelli L., Park J.S. Laboratory and clinical aspects of human papillomavirus testing. Crit. Rev. Clin. Lab. Sci. 2012, 49(4):117-136.
36. Haedicke J., Iftner T. A review of the clinical performance of the aptima HPV assay. J. Clin. Virol. 2015, HPV Suppl-this issue.
37. Franco E.L., de Sanjosé S., Broker T.R., Stanley M.A., Chevarie-Davis M., Isidean S.D., et al. Human papillomavirus and cancer prevention: gaps in knowledge and prospects for research, policy, and advocacy. Vaccine 2012, 30(Suppl. 5):F175-F182.
38. Eklund C., Zhou T., Dillner J. WHO human papillomavirus laboratory network global proficiency study of human papillomavirus genotyping. J. Clin. Microbiol. 2010, 48(11):4147-4155.
39. Eklund C., Forslund O., Wallin K.L., Dillner J. Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV LabNet international proficiency study. J. Clin. Microbiol. 2014, 52(2):449-459.
40. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 2005, 97(14):1072-1079.
41. von Karsa L., Arbyn M., De Vuyst H., Dillner J., Dillner L., Franceschi S., et al. European guidelines for quality assurance in cervical cancers screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015, In press.
42. Huh W.K., Ault K.A., Chelmow D., Davey D.D., Goulart R.A., Garcia F.A., et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol. Oncol. 2015, 136(2):178-182.
43. Denham O., Garland S.M., Gorelik A., Ogilvie G., Tan J., Mazza D., et al. Attitudes of changes in cervical screening: views of Australian general practitioners and nurses. J. Clin. Virol. 2015, HPV Suppl-this issue.
44. Schutzbank T.E., Ginocchio C.C. Assessment of clinical and analytical performance characteristics of an HPV genotyping test. Diagn. Cytopathol. 2012, 40(4):367-373.
45. Eklund C., Forslund O., Wallin K.L., Zhou T., Dillner J. WHO Human Papillomavirus Laboratory Network, The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J. Clin. Microbiol. 2012, 50(7):2289-2298.
46. C. Eklund, KL., Wallin, O., Forslund, J. Dillner, Technical Report on the global HPV LabNet 2013HPV DNA genotyping proficiency panel, retrieved 26/10/2015. http://www.hpvcenter.se/attachements/WHO_HPV_DNA_PP_2013_Final_summary_report.pdf.
47. Schmitt M., Dondog B., Waterboer T., Pawlita M., Tommasino M., Gheit T. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping test. J. Clin. Microbiol. 2010, 48(1):143-149.
48. Cuschieri K., Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol. Biomarkers Prev. 2008, 17(10):2536-2545.
49. Burger E.A., Kornør H., Klemp M., Lauvrak V., Kristiansen I.S. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol. Oncol. 2011, 120(3):430-438.
50. Witonsky J. Infectious disease molecular diagnostics market review and opportunities. Genetic Eng. Biotechnol. News 2011, 31. 14.
51. Luhn P., Wentzensen N. HPV-based tests for cervical cancer screening and management of cervical disease. Curr. Obstet. Gynecol. Rep. 2013, 2(2):76-85.
52. Stoler M.H., Castle P.E., Solomon D., Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am. J. Clin. Pathol. 2007, 127(3):335-337.
53. Gravitt P.E., Coutlée F., Iftner T., Sellors J.W., Quint W.G., Wheeler C.M. New technologies in cervical cancer screening. Vaccine 2008, 26(Suppl. 10):K42-K52.
54. Arbyn M., Ronco G., Cuzick J., Wentzensen N., Castle P.E. How to evaluate emerging technologies in cervical cancer screening?. Int. J. Cancer 2009, 125(11):2489-2496.
55. Cuschieri K., Bhatia R., Cruickshank M., Hilemanns P., Arbyn M. HPV testing in the context of post-treatment follow up (test-of-cure). J. Clin. Virol. 2015, HPV Suppl-this issue.
56. Carozzi F.M., Del Mistro A., Cuschieri K., Frayle H., Sania C., Burroni E. HPV testing for primary cervical screening: Laboratory issues and evolving requirements for robust quality assurance. J. Clin. Virol. 2015, HPV Suppl-this issue.
57. Kocjan B.J., Hošnjak L., Poljak M. Detection of alpha human papillomaviruses in archival formalin-fixed, paraffin-embedded (FFPE) tissue specimens paraffin. J. Clin. Virol. 2015, HPV Suppl-this issue.
58. Fagan E.J., Moore C., Jenkins C., Rossouw A., Cubie H.A., James V.L. External quality assessment for molecular detection of human papillomaviruses. J. Clin. Virol. 2010, 48(4):251-254.
59. Tabrizi S.N. Quality assessment for human papillomavirus testing. Sex Health 2010, 7(3):335-337.
60. Szarewski A., Ambroisine L., Cadman L., Austin J., Ho L., Terry G., et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol. Biomarkers Prev. 2008, 17(11):3033-3042.
61. Szarewski A., Mesher D., Cadman L., Austin J., Ashdown-Barr L., Ho L., et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J. Clin. Microbiol. 2012, 50(6):1867-1873.
62. Garland S.M., Molesworth E.G., Machalek D.A., Cornall A.M., Tabrizi S.N. How to best measure the effectiveness of male human papillomavirus vaccine programmes?. Clin. Microbiol. Infect. 2015, 21(9):834-841.
63. Vorsters A., Van den Bergh J., Micalessi I., Biesmans S., Bogers J., Hens A., et al. Optimization of HPV DNA detection in urine by improving collection, storage, and extraction. Eur. J. Clin. Microbiol. Infect. Dis. 2014, 33(11):2005-2014.
64. Vorsters A., Van Keer S., Van Damme P. The use of urine in the follow-up of HPV vaccine trials. Hum. Vaccin. Immunother. 2015, 11(2):350-352.
65. Qiao Y.L., Sellors J.W., Eder P.S., Bao Y.P., Lim J.M., Zhao F.H., et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008, 9(10):929-936.